This real-life study assessed the effectiveness and tolerance of upadacitinib in severe atopic dermatitis in a series of 29 adults and adolescents with a median follow-up of 54.4 weeks

Upadacitinib was effective, also in severe and recalcitrant atopic dermatitis after failure of treatment with biologics or baricitinib

Effectiveness of upadacitinib 15 mg suggests that it could be considered as a starting dose for older patients, in case of comorbidities, or as a tapered dose for responders

Induced lipid changes were the most frequent adverse events, requiring close follow-up